Safety and Efficacy of House Dust Mite Allergoid in the Treatment of Bronchial Asthma

• Status: Completed
• Trial end date: 2012-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The trial is performed to assess efficacy and safety of the Allergopharma house dust mite allergoid in bronchial asthma.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergopharma GmbH & Co. KG
• Treatments: Aluminum Hydroxide

Criteria

Inclusion Criteria:

• Bronchial asthma

• Requirements for inhaled corticosteroid

• Positive skin prick test to house dust mite

• Positive radioallergosorbent test (RAST) to house dust mite

• Positive provocation test result to house dust mite

Exclusion Criteria:

• Serious chronic diseases

• Other perennial allergies